{'fraction_non_alphanumeric': 0.01589242053789731, 'fraction_numerical': 0.019559902200488997, 'mean_word_length': 4.978102189781022, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immune complexes associated with brain tumors: correlation with prognosis.

The presence of circulating immune complexes in the sera of 208 patients with intracranial space occupying lesions was assayed using the C1 q binding test. Twenty-eight percent of 96 high grade glioma patients had immune complexes as compared to 14% of 28 low grade glioma patients. The incidence of immune complexes was found to decrease in the first post-operative month. The presence of immune complexes correlated with shorter survival in a group of malignant glioma patients tested preoperatively. Nineteen patients without immune complexes had a mean survival of 8.6 months as compared to 13 patients with immune complexes who had a mean survival of 4.7 months. These results confirm similar observations in other types of malignancies.